ClinicalTrials.gg
RecruitingNCT07664397Updated Oct 1, 2026

Imaging Study of [89Zr]DFO-YS5 for Cancer Detection

A Phase 1 interventional study of [89Zr]DFO-YS5 and Positron Emission Tomography (PET)-Computerized tomography (CT) in Bladder Cancer, Nerve Sheath Tumor and Nerve Sheath Tumors, sponsored by Robert Flavell, MD, PhD. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Robert Flavell, MD, PhD · Phase 1, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 1, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 883 studies in Urinary Bladder Neoplasms with a site in United States — 162 open to participants now, 269 under way, 31 of them phase 3. Urinary Bladder Neoplasms · United States.

Planned enrollment
386th of 715
40 · median 46
Started
2026
with 39 others
Phase 1
198 of 883
27 open now
Primary completion
2029-09
later than 233 of 266 live
Registered
867th of 883
by date

Among the 883 studies in Urinary Bladder Neoplasms with a site in United States, this one is the 386th largest by planned enrollment of the 715 interventional ones that give a count, is one of 40 that started in 2026, is one of 198 in phase 1, reaches primary completion later than 233 of the 266 other live ones, and was the 867th registered.

Urinary Bladder Neoplasms

1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

162 of the 883 studies in Urinary Bladder Neoplasms with a site in United States are open now. Recruiting first, the newest first:

156 more — sign in →

All 162 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 883 studies in Urinary Bladder Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a single-center, pilot, PET-imaging study of the novel radiotracer 89Zirconium-89 DFO conjugated to the YS5 monoclonal antibody ([89Zr]DFO-YS5) in participants with nerve sheath tumor, bladder cancer, or advanced solid tumor neoplasms.

Read the detailed description

PRIMARY OBJECTIVE:

I. To descriptively report patterns of [89Zr]DFO-YS5 uptake on whole-body PET.

SECONDARY OBJECTIVE:

II. To determine the safety of [89Zr]DFO-YS5.

OUTLINE:

Participants will be administered a single dose of [89Zr]DFO-YS5 followed by whole-body positron emission tomography (PET) imaging at a single time point. All participants will be followed for adverse events for approximately Participants in the main study will be followed for adverse events for approximately 1 month after [89Zr]DFO-YS5 radiotracer administration.

03

Conditions studied

  • Bladder Cancer
  • Nerve Sheath Tumor
  • Nerve Sheath Tumors
  • Solid Tumor Malignancies
  • Solid Tumor Cancer
  • Solid Tumor Neoplasms
  • Advanced Solid Tumor
  • Bladder Neoplasm
  • Nerve Sheath Neoplasms
  • Nerve Sheath Tumor, Nos
  • Solid Tumor, Adult
  • Solid Carcinoma

Keywords

  • Imaging Study
04

Who can participate

The criteria were revised on the registry on Oct 1, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Histological or cytological confirmation of malignant peripheral nerve sheath tumor, bladder cancer, or solid tumor neoplasm.
  2. At least one soft tissue lesion measurable at 1 cm or greater in short axis measurement on cross sectional imaging such as Computerized tomography (CT), magnetic resonance imaging (MRI), or Positron Emission Tomography (PET)/CT (scan imaging as documented in the medical record). Exception: For participants with localized bladder cancer (pre-cystectomy), lesions smaller than 1 centimeter (cm) are permitted, provided there is cystoscopic confirmation of a bladder mass.
  3. Clinically able to undergo PET-CT imaging.
  4. Age ≥ 18 years.
  5. (ECOG) performance status of ≤ 2 or ≥ 50% (see Appendix 1).
  6. Adequate organ function as defined below:

    • Total : ≤ 1.5 x institutional (ULN) (unless elevated due to Gilbert's syndrome and direct bilirubin is within normal limits).
    • (AST) (serum glutamic-oxaloacetic transaminase (SGOT)): ≤ 3 x ULN.
    • Alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase (SGPT)): ≤ 3 x ULN.
    • Estimated : ≥ 30 mL/min, calculated using the Cockcroft-Gault equation.
  7. Females of (defined below) must be willing to undergo a urine or serum pregnancy test (i.e., human chorionic gonadotropin test) within 72 hours before administration of [89Zr]DFO-YS5. A female is considered to NOT be of reproductive potential (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice), if they meet either of the following two criteria: (1) has reached a state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause); or (2) has undergone surgical sterilization (i.e., hysterectomy and/or bilateral oophorectomy for removal of uterus and/or ovaries). The result of the urine or serum pregnancy test must be negative in order to initiate the [89Zr]DFO-YS5 administration. If a urine pregnancy test is positive or equivocal, a confirmatory a serum pregnancy test is required. The individual must be excluded from participation if the serum pregnancy result is positive. Pregnant individuals are excluded from this study because there is an unknown but potential risk for adverse effects in the unborn child secondary to treatment of the study participant with [89Zr]DFO-YS5.
  8. Individuals with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or endpoints of this study are eligible.
  9. Ability to understand and the willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  1. Individuals with a to PET-CT imaging (e.g., severe claustrophobia) (e.g., implanted devices, metallic objects, or other implants). Participants must be able to undergo either PET-CT.
  2. Individuals who are pregnant or breastfeeding/chest-feeding.

    • Breastfeeding/chestfeeding should be discontinued before administration of [89Zr]DFO-YS5.
    • Females of (defined below) must have a negative urine or serum pregnancy test (i.e., human chorionic gonadotropin test) within 72 hours prior to administration of [89Zr]DFO-YS5. If the urine pregnancy test is positive or equivocal, a confirmatory serum pregnancy test is required. In such cases, the individual must be excluded from participation if the serum pregnancy result is positive.

    A female is considered to be of childbearing potential (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice), unless it is documented that the individual meets either of the following two criteria: (1) has reached a state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause); or (2) has undergone surgical sterilization (i.e., hysterectomy and/or bilateral oophorectomy for removal of uterus and/or ovaries).

    Individuals who are pregnant or breastfeeding/chestfeeding are excluded because there is an unknown but potential risk for adverse effects in the unborn/nursing child secondary to treatment of the study participant with [89ZR]-DFO-YS5.

  3. to [89Zr]DFO-YS5 or any of its .
  4. Individuals with any condition or social circumstance that, in the opinion of the investigator, would impair the participant's ability to comply with study procedures.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Treatment ([89Zr]DFO-YS5)

    Participants will be administered a single, intravenous microdose (1.0 - 3.0 mCi) of \[89Zr\]DFO-YS5, followed by whole-body positron emission tomography (PET) imaging conducted 120-168 hours after \[89Zr\]DFO-YS5 administration (i.e., on Day 6-8). Participants will be followed for treatment-emergent adverse events for up to 35 days.

    Drug: [89Zr]DFO-YS5 · Procedure: Positron Emission Tomography (PET)-Computerized tomography (CT)

Interventions

  • DrugZirconium-89Studies of Zirconium-89Zirconium-89 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given intravenously (IV)

    Also known as: 89Zirconium-89 DFO conjugated to the YS5 monoclonal antibody

  • ProcedurePositron Emission Tomography (PET)-Computerized tomography (CT)

    Participants may receive a whole-body PET-CT or a whole-body PET-MRI

    Also known as: PET/CT, PET-CT

06

What researchers measure

Primary outcomes

  1. Mean maximum standard uptake value (SUVmax-avg) on Positron Emission Tomography (PET) scan

    A volume of interest (VOI) will be placed around each lesion, and the calculated maximum standard uptake value (SUVmax) will be recorded for each lesion. Adjusted SUVmax data will then be averaged across up to 15 lesions within a given patient (SUVmax-avg) at each time point. In order to avoid clustering effects, analyses will be limited to the five largest osseous metastases, five largest lymph node metastases, and five largest visceral/soft tissue metastases. Metastatic lesion location, size (bidimensional axial measurement), and SUVmax will be tabulated. This will be conducted for all lesions.

    Time frame: Up to 8 days

  2. Median intra-tumoral SUVmax

    The median and range for intra-tumoral SUVmax within metastatic lesions will be descriptively reported, to assess for intra-tumoral heterogeneity and differences in uptake by site of disease.

    Time frame: Up to 8 days

  3. Tumor-to-background signal (Ratio)

    The tumor-to-background signal refers to comparing the standardized uptake value (SUV) of a lesion (tumor) to the SUV of a nearby normal organ or tissue that serves as a "background" reference. The ratio of the tumor-to-background signal on PET scan (normal organ as background uptake values) will be calculated as the SUVmax of tumor divided by the SUV of background organ

    Time frame: Up to 8 days

Secondary outcomes

  1. Proportion of participants with reported treatment-emergent adverse events

    The proportion of participants with reported treatment-emergent Adverse events (AEs) will be classified and graded according to the NCI CTCAE version. 5.0 by severity and type evaluated from the time of administration through the Day 6-8 Visit (120-168 hours post-dose).

    Time frame: Up to 8 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified data may be shared with study collaborators during the course of data collection.

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Sep 2029, 39 months after the start.

Of 65 non-industry phase 1 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's planned 39 months is below that.

Counting every sponsor, half of 145 studies reached it within 43 months; a quarter within 29 and three quarters within 66.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Jun 2026, on Oct 1, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2026
First posted
Jun 24, 2026
StartActual
Jun 15, 2026was Aug 2026
Primary completionEst.
Sep 30, 2029
CompletionEst.
Sep 30, 2029
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 1, 2026
Sites
University of California, San Francisco is now Recruiting
Oct 1, 2026
Start date
Aug 1, 2026→Jun 15, 2026 (actual)
Oct 1, 2026
Eligibility
2 inclusion criteria edited; 3 exclusion criteria edited, 3 added, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedClinically able to undergo PET-CT imaging or PET-MRI.
  • EditedEstimated creatinine clearance: ≥ 6030 mL/min, calculated using the Cockcroft-Gault equation.
Exclusion criteria
  • EditedIndividuals with a contraindication to PET-CT imaging (e.g., severe claustrophobia) or PET-MRI (e.g., implanted devices, metallic objects, or other implants). Participants must be able to undergo either PET-CT or PET-MRI.
  • AddedIndividuals who are pregnant or breastfeeding/chest-feeding.
  • AddedBreastfeeding/chestfeeding should be discontinued before administration of [89Zr]DFO-YS5.
  • AddedFemales of childbearing potential (defined below) must have a negative urine or serum pregnancy test (i.e., human chorionic gonadotropin test) within 72 hours prior to administration of [89Zr]DFO-YS5. If the urine pregnancy test is positive or equivocal, a confirmatory serum pregnancy test is required. In such cases, the individual must be excluded from participation if the serum pregnancy result is positive.
  • EditedFemales of reproductive potential (defined below) must agree to use two forms of contraception, consisting of a barrier method (such as condoms) in combination with a secondary complementary method (such as hormonal, Intrauterine device (IUD), etc.), or strict abstinence, for the duration of study participation and for 1 month after administration of [89Zr]DFO-YS5. A female is considered to NOT be of reproductivechildbearing potential (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice), if they meetunless it is documented that the individual meets either of the following two criteria: (1) has reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause); or (2) has undergone surgical sterilization (i.e., hysterectomy and/or bilateral oophorectomy for removal of uterus and/or ovaries).
  • EditedIndividuals who are pregnant or breastfeeding/chest-feeding. Pregnant and breastfeeding/chest-feeding individualschestfeeding are excluded because there is an unknown but potential risk for adverse effects in the unborn/nursing child secondary to treatment of the study participant with [89Zr89ZR]-DFO-YS5. Females of childbearing potential must have a negative pregnancy test before administration of [89Zr]DFO-YS5, as outlined in inclusion criterion #7. Breastfeeding/chest-feeding should be discontinued before administration of [89Zr]DFO-YS5.
  • RemovedIndividuals who do not agree to follow the below contraception requirements:
Oct 1, 2026
Interventions
Removed Procedure: Positron Emission Tomography (PET)-Magnetic resonance imaging (MRI)
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Not yet recruiting→Recruiting
    University of California, San Francisco is now Recruiting
    Start date Aug 1, 2026→Jun 15, 2026 (now actual)
    Eligibility 2 inclusion criteria edited; 3 exclusion criteria edited, 3 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedClinically able to undergo PET-CT imaging or PET-MRI.
    • EditedEstimated creatinine clearance: ≥ 6030 mL/min, calculated using the Cockcroft-Gault equation.
    Exclusion criteria
    • EditedIndividuals with a contraindication to PET-CT imaging (e.g., severe claustrophobia) or PET-MRI (e.g., implanted devices, metallic objects, or other implants). Participants must be able to undergo either PET-CT or PET-MRI.
    • AddedIndividuals who are pregnant or breastfeeding/chest-feeding.
    • AddedBreastfeeding/chestfeeding should be discontinued before administration of [89Zr]DFO-YS5.
    • AddedFemales of childbearing potential (defined below) must have a negative urine or serum pregnancy test (i.e., human chorionic gonadotropin test) within 72 hours prior to administration of [89Zr]DFO-YS5. If the urine pregnancy test is positive or equivocal, a confirmatory serum pregnancy test is required. In such cases, the individual must be excluded from participation if the serum pregnancy result is positive.
    • EditedFemales of reproductive potential (defined below) must agree to use two forms of contraception, consisting of a barrier method (such as condoms) in combination with a secondary complementary method (such as hormonal, Intrauterine device (IUD), etc.), or strict abstinence, for the duration of study participation and for 1 month after administration of [89Zr]DFO-YS5. A female is considered to NOT be of reproductivechildbearing potential (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice), if they meetunless it is documented that the individual meets either of the following two criteria: (1) has reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause); or (2) has undergone surgical sterilization (i.e., hysterectomy and/or bilateral oophorectomy for removal of uterus and/or ovaries).
    • EditedIndividuals who are pregnant or breastfeeding/chest-feeding. Pregnant and breastfeeding/chest-feeding individualschestfeeding are excluded because there is an unknown but potential risk for adverse effects in the unborn/nursing child secondary to treatment of the study participant with [89Zr89ZR]-DFO-YS5. Females of childbearing potential must have a negative pregnancy test before administration of [89Zr]DFO-YS5, as outlined in inclusion criterion #7. Breastfeeding/chest-feeding should be discontinued before administration of [89Zr]DFO-YS5.
    • RemovedIndividuals who do not agree to follow the below contraception requirements:
    Interventions Removed Procedure: Positron Emission Tomography (PET)-Magnetic resonance imaging (MRI)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07664397
Lead sponsor
Robert Flavell, MD, PhD
Collaborators
Kyntra Bio, Fortis Therapeutics, Inc.
Responsible party
Robert Flavell, MD, PhD (Principal Investigator, University of California, San Francisco) — Sponsor-investigator
First posted
Jun 24, 2026
Start date
Jun 15, 2026
Primary completion
Sep 30, 2029 (estimated)
Completion
Sep 30, 2029 (estimated)
Last update
Oct 1, 2026

Study contacts

Maya Aslam
Contact
Maya.Aslam@ucsf.edu
877-827-3222
Robert Flavell, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zirconium-89

Start the discussion